StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Rivastigmine

HCID 77991
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
123441-03-2
Standard-SMILES
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
Summenformel
C14H22N2O2
Durchschnittliche Molmasse
250,34 g/mol
Monoisotopische Masse
250,16812795

Überblick

Rivastigmine is a carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a cholinergic drug and a neuroprotective agent. It is a carbamate ester and a tertiary amino compound. It is a conjugate base of a rivastigmine(1+).

Namen und Bezeichner

Bevorzugter Name
Rivastigmine
IUPAC
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
Englischer Name
Rivastigmine
Summenformel
C14H22N2O2
Molmasse
250.34

Namen und Synonyme

rivastigmine123441-03-2PrometaxENA 713 free baseNimvastidRivastigmine Tevarivastigmine hexalRivastigminaRivastigmine sandozSDZ-ENA-713Rivastigmine Transdermal SystemSDZ-212-713
Weitere Namen anzeigen
RIVASTIGMINE HYDROGEN TARTRATEmineEXELONRivastigmine baseRivastigKabaratincabalatineRevastigmineRivastigiMine
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamatem-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamateONO-2540PKI06M3IW0SDZ 212-713ENA-713D3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamateSDZ-212713

Datenbank-Bezeichner

CAS
123441-03-2
PubChem CID
77991
DTXSID
DTXSID7023564
ChEMBL
CHEMBL636
ChEBI
CHEBI:8874
UNII
PKI06M3IW0

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,3
Polarare Oberfläche (TPSA)
32,8 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
5
Schwere Atome
18
Formalladung
0
Komplexität
269

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Acetylcholinesterase inhibitor

LogP2.3
Solubility2.04e+00 g/L
Human Drugs · 6 Einträge

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Physical DescriptionSolid
Dissociation Constants · 2 Einträge

8.8

8.99

Collision Cross Section165 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physikochemische Eigenschaften

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 6.2% (1 of 16) of reports.

Danger

H300 (31.2%): Fatal if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P317, P321, P330, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 16 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 2 (31.2%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

In large placebo controlled trials, rivastigmine therapy was not associated with an increased rate of serum enzyme elevations compared to placebo treatment and no instances of clinically apparent liver injury with jaundice were reported. Nevertheless, since its introduction into clinical use, rivastigmine (administered by transdermal patch) has been implicated in at least one report of clinically apparent hepatotoxicity with mild jaundice. The time to onset was 2 months and the serum enzyme elevations had a mildly hepatocellular pattern. Mild rash and eosinophilia were also present, but autoimmune features were not. Recovery was complete within 5 weeks of drug discontinuation.

Adverse Effects · 1 Eintrag

Adverse effects of rivastigmine have received thorough study as it has been on the market for some time. The main adverse effects associated with the use of rivastigmine are gastrointestinal. The primary symptoms are nausea and vomiting. These acute effects primarily occur during the initial dose-escalation phase of therapy with upward dose titration of the drug to achieve a therapeutic dose. These events can be minimized using a slow titration schedule and taking the medication with food if prescribing an oral formulation. In a study done to analyze the safety and tolerability of cholinesterase inhibitors used to treat Alzheimer dementia, researchers found rivastigmine to be the drug to have the highest rate of gastrointestinal side effects.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

N06DA03

N - Nervous system

QN - Nervous system

Protein Binding40%
Pharmacodynamics · 1 Eintrag

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.

Mechanism of Action · 1 Eintrag

Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

Biological Half-Life1.5 hours
Metabolism/MetabolitesRivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.
FDA Pharmacological Classification · 6 Einträge

Zugehörige Reaktionen

3
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 532100
HRID 532100als Produkt
Reaktionsgleichung von HRID 907502
HRID 907502als Edukt
Reaktionsgleichung von HRID 1425636
HRID 1425636als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
EC Number
602-936-0
Nikkaji
J982.502I
Siedepunkt
316.2 · 316.2±34.0 °C(Predicted)
Dichte
1.038 · 1.038±0.06 g/cm3(Predicted)
Flammpunkt
145 ℃ · 145℃
storage temp.
-20 °C · Sealed in dry,Store in freezer, under -20°C
Löslichkeit
Chloroform (Sparingly), Ethyl Acetate (Slightly)
Aggregatzustand
Powder
pka
8.99 · pKa 8.99 (Uncertain)
Farbe
Colorless to light yellow
Major Application
pharmaceutical (small molecule)
InChI
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
SMILES
C(OC1=CC=CC([C@@H](N(C)C)C)=C1)(=O)N(CC)C
CAS Datenbank
123441 · 123441-03-2(CAS DataBase Reference)
Toxicity Summary · 1 Eintrag

Toxicity to the drug, while rare, should be carefully monitored. Common toxicity manifestations include severe gastrointestinal reactions, allergic cutaneous reactions, and central nervous system effects. All cutaneous reactions due to usage of the patch should prompt immediate removal of the patch for at least 48 hours before reapplying in a new area. Therapy should be discontinued if symptoms last longer than 48 hours or a severe cutaneous reaction occurs.

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

rivastigmine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Sicherheitsdaten

wgk
WGK 3
ridadr
UN 2810 6.1 / PGIII
hs_code
2924296000
Speicherklasse
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
Acute Tox. 2 OralAquatic Chronic 2

PKI06M3IW0

RIVASTIGMINE

Established Pharmacologic Class [EPC] - Cholinesterase Inhibitor

Mechanisms of Action [MoA] - Cholinesterase Inhibitors

Rivastigmine is a Cholinesterase Inhibitor. The mechanism of action of rivastigmine is as a Cholinesterase Inhibitor.

RIVASTIGMINE

MeSH Pharmacological Classification · 2 Einträge

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and Excretion · 3 Einträge

Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.

1.8 to 2.7 L/kg

renal cl=2.1-2.8 L/hr

Cellular LocationsCytoplasm

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >100
Anwendungen · 2 Einträge

HistoryRivastigmine was discovered by Marta Weinstock-Rosin of the Department of Pharmacology at the Hebrew University of Jerusalem and sold to Novartis by Yissum for commercial development. Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease.

VerwendenAntidepressant

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

(S)-1-(3-(ethyl(methyl)carbamoyloxy)phenyl)-N,N-dimethyl-N-((S)-1-phenylethyl)ethanaminium iodideRivastigmine hydrochlorideCarbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-aminoethyl]phenyl ester1257519-35-9Methanamine, N-(benzoyloxy)-N-methyl-3-(1-(Dimethylamino)ethyl]phenol3-[(1S)-1-(Dimethylaminoethyl)]phenolEthylmethyl-carbamic chlorideRivastigmine EP Impurity E3-(1-hydroxyethyl)phenyl ethyl(methyl)carbamate(R)-3-(1-hydroxyethyl)phenylethyl(methyl)carbamate

Ergänzende Hinweise

DefinitionChEBI: A carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor.